Sanofi has released a second brand formulation of insulin glargine 100 units/ml. The new preparation is called OPTISULIN® and is already listed on the Pharmaceutical Benefits Scheme (PBS) as of 1st January, 2020. It is currently listed alongside LANTUS® which will be removed from the PBS as of the 1st July, 2020. Read more for what you need to know:
OPTISULIN® is a second brand of insuline glargine 100 units/ml and is ‘A’ flagged, which means pharmacies can substitute without prescriber endorsement.
The formulation, excipients and manufacturing process of OPTISULIN® is the same as LANTUS®.
People currently using LANTUS® may transition to OPTISULIN®. No dose adjustment is required when transitioning from LANTUS® to OPTISULIN® and patients should continue to titrate/adjust their dose as directed by their treating clinician.
OPTISULIN® is available in disposable pens (SoloStar®) and cartridges for reusable pens (AllStar Pro® and JuniorStar®). The cartridges will fit in existing Sanofi reusable pens.
As with LANTUS®, reusable pens from other companies are not correctly calibrated for OPTISULIN® dosing and should not be used.
Toujeo (insulin glarginr 300 units/ml) will continue as previously.
Through a partnership with the Australian Diabetes Educators Association (ADEA), Sanofi insulin patients can call 1900 2 746 753 and speak with a Credentialled Diabetes Educator (CDE). This includes a translator service and is free.
OPTSULIN® PBS code is 9039R.
Cartridges or disposable pens quantity 5 packs of 5 cart/pens with 1 repeat
Safety price $41.00 general and $6.60 concessional